Albireo Pharma Inc Stock Research

Market Summary

USD44.07+0.12

Market Closed

0.27%

ALBO Alerts

1 major insider sales recently.

ALBO Stock Price

ALBO RSI Chart

ALBO Valuation

Market Cap

911.9M

Price/Earnings (Trailing)

-6.95

Price/Sales (Trailing)

15.89

EV/EBITDA

-4.57

Price/Free Cashflow

-7.84

ALBO Price/Sales (Trailing)

ALBO Profitability

Operating Margin

95.56%

EBT Margin

-263.46%

Return on Equity

-131.05%

Return on Assets

-40.83%

Free Cashflow Yield

-12.75%

ALBO Fundamentals

ALBO Revenue

Revenue (TTM)

57.4M

Revenue Y/Y

168.34%

Revenue Q/Q

19.81%

ALBO Earnings

Earnings (TTM)

-131.1M

Earnings Y/Y

-166.22%

Earnings Q/Q

5.38%

Price Action

52 Week Range

16.0244.40

(Low)(High)

Last 7 days

0.6%

Last 30 days

123.6%

Last 90 days

107.9%

Trailing 12 Months

71.6%

ALBO Financial Health

Current Ratio

6.32

ALBO Investor Care

Shares Dilution (1Y)

7.44%

Diluted EPS (TTM)

-6.72

Peers (Alternatives to Albireo Pharma)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	350.6B	1.2B	18.44%	28.04%	-166.6	280.55	17.64%	-57.08%
ABBV	259.1B	57.8B	-9.83%	10.63%	19.32	4.48	4.80%	77.95%
VRTX	82.5B	8.7B	12.49%	40.85%	25.2	9.48	22.03%	50.41%
REGN	79.4B	15.0B	4.18%	22.03%	14.79	5.14	21.25%	-23.23%
ALNY	28.5B	960.9M	-0.11%	81.92%	-24.07	29.61	28.24%	-41.08%
UTHR	11.8B	1.9B	-5.00%	33.05%	16.73	6.36	12.37%	52.98%
SRPT	10.8B	876.0M	-2.75%	83.75%	-15.06	12.31	35.70%	-47.34%
MID-CAP
MDGL	5.0B	504.0K	6.89%	417.98%	-18.07	2.5K	-66.53%	-15.89%
RARE	3.1B	343.4M	0.46%	-32.04%	-4.52	8.92	-4.50%	-90.69%
MRTX	3.1B	-	26.46%	-50.77%	-4.14	917.1	-	-52.72%
BPMC	2.9B	272.3M	13.28%	-31.85%	-3.98	10.5	-18.36%	-74.56%
SMALL-CAP
CPRX	1.6B	191.8M	-14.40%	192.28%	24.14	8.42	43.59%	60.82%
MGNX	352.8M	93.0M	0.88%	-49.25%	-1.85	3.79	-19.83%	-30.37%
CRBP	18.1M	-	32.75%	-64.96%	-0.43	19.11	-77.61%	5.14%
CYTK	4.0M	-	-5.44%	44.99%	-0.01	63.29	26.15%	-23.38%

Financials for Albireo Pharma

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	12.0%	57,391,000	51,223,000	45,445,000	40,579,000	10,774,000
Gross Profit	229.7%	39,223,000	11,898,000	-	-	-
Operating Expenses	0.9%	178,947,000	177,303,000	167,354,000	162,708,000	144,167,000
S&GA Expenses	3.9%	78,763,000	75,811,000	71,151,000	69,569,000	63,983,000
R&D Expenses	2.6%	88,705,000	86,476,000	84,482,000	82,522,000	81,970,000
EBITDA	-347.7%	-150,771,000.00	-33,679,000.00	-33,756,000.00	-	-
EBITDA Margin	-254.5%	-2.63	-0.74	-0.83	-	-
Earnings Before Taxes	-162.1%	-151,200,000.00	243,500,000	-	-	-
EBT Margin	-251.8%	-2.63	-0.75	-0.84	-	-
Net Income	-261.7%	-131,145,000.00	-36,259,000.00	-32,731,000.00	-34,030,000.00	-47,867,000.00
Net Income Margin	-222.8%	-2.29	-0.71	-0.72	-0.84	-
Free Cahsflow	-1.8%	-116,282,000.00	-114,281,000.00	-108,813,333.33	-108,024,000.00	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	40.3%	321	229	261	302	296
Current Assets	22.0%	239	196	229	269	272
Cash Equivalents	22.9%	222	181	217	248	263
Inventory	50.2%	3	2	2	0	0
Net PPE	-6.1%	1	1	1	1	1
Goodwill	0%	17	17	17	17	17
Liabilities	91.7%	221	115	113	126	115
Current Liabilities	-13.2%	38	44	32	45	33
Shareholder's Equity	-12.0%	100	114	148	176	182
Retained Earnings	-9.9%	-421.03	-383.23	-343.28	-300.85	-289.89
Additional Paid-In Capital	5.0%	513	489	483	475	472
Shares Outstanding	5.6%	21	20	20	19	19

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-1.9%	-115.32	-113.17	-108.25	-107.56	-121.86
Share Based Compensation	-19.2%	13	16	16	16	18
Cashflow From Investing	-100.9%	-0.96	102	137	103	206
Cashflow From Financing	1650.8%	128	7	7	3	3
Buy Backs	-75.0%	0	1	-	-	-

Risks for ALBO

What is the probability of a big loss on ALBO?

98.1%

Probability that Albireo Pharma stock will be more than 20% underwater in next one year

80%

Probability that Albireo Pharma stock will be more than 30% underwater in next one year.

63.9%

Probability that Albireo Pharma stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ALBO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Albireo Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for ALBO

Cumulative Returns on ALBO

-6.2%

10-Year Cumulative Returns

28.9%

7-Year Cumulative Returns

3.7%

5-Year Cumulative Returns

22%

3-Year Cumulative Returns

What are the long-term rolling returns for ALBO?

FIve years rolling returns for Albireo Pharma.

Annualized Returns

Which funds bought or sold ALBO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-25	Lindbrook Capital, LLC	reduced	-41.08	-5,010	8,990	-%
2023-01-24	NATIONAL BANK OF CANADA /FI/	unchanged	-	123	4,123	-%
2023-01-23	Sargent Bickham Lagudis LLC	unchanged	-	483	6,483	-%
2023-01-23	Allspring Global Investments Holdings, LLC	reduced	-39.02	-9,390	21,610	-%
2023-01-20	Chicago Capital, LLC	added	21.68	7,764,280	29,443,300	1.63%
2023-01-13	Allworth Financial LP	added	408.33	1,318	1,318	-%
2022-11-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-0.49	-13,000	425,000	-%
2022-11-17	M&T Bank Corp	added	17.03	60,000	484,000	-%
2022-11-16	CAPTRUST FINANCIAL ADVISORS	sold off	-100	-2,000	-	-%
2022-11-16	BNP PARIBAS ARBITRAGE, SNC	added	112.86	138,812	267,942	-%

Latest Funds Activity

Are funds buying ALBO calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ALBO

No. of Funds

ALBO Alerts

1 major insider sales recently.

Albireo Pharma News

Schedule 13G FIlings of Albireo Pharma

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 23, 2023	chicago capital, llc	6.6%	1,362,484	SC 13G
Oct 03, 2022	deep track capital, lp	5.46%	1,124,421	SC 13G
Sep 26, 2022	tang capital partners lp	5.6%	1,099,516	SC 13G
Mar 07, 2022	chicago capital, llc	5.1%	971,885	SC 13G
Feb 14, 2022	federated hermes, inc.	12.23%	2,358,624	SC 13G/A
Feb 14, 2022	perceptive advisors llc	12.2%	2,360,139	SC 13G/A
Feb 09, 2022	state street corp	5.15%	992,832	SC 13G
Feb 03, 2022	blackrock inc.	6.1%	1,168,783	SC 13G/A
Feb 16, 2021	perceptive advisors llc	12.4%	2,360,139	SC 13G/A
Feb 16, 2021	arrowmark colorado holdings llc	3.9%	751,495	SC 13G/A

ALBO Fair Value

Recent SEC filings of Albireo Pharma

View All Filings

Date Filed	Form Type	Document
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 25, 2023	4	Insider Trading
Jan 23, 2023	SC 13G	Major Ownership Report
Jan 23, 2023	SC 14D9	SC 14D9

Latest Insider Trading transactions for ALBO

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-01-23	Cooper Ronald Harold Wilfred	sold	-46,296.6	43.8	-1,057	president and ceo
2023-01-23	Carter Martha J.	sold	-5,256	43.8	-120	chief regulatory officer
2023-01-23	Harford Simon N.R.	sold	-4,467.6	43.8	-102	cfo and treasurer
2023-01-23	Stephenson Pamela	sold	-4,467.6	43.8	-102	chief commercial officer
2023-01-23	Duncan Jason	sold	-9,986.4	43.8	-228	chief legal officer and gc
2023-01-23	Graham Michelle	sold	-4,467.6	43.8	-102	chief human resources officer
2023-01-23	Mattsson Jan	sold	-8,628.6	43.8	-197	chief scientific officer
2023-01-19	Carter Martha J.	acquired	-	-	55,000	chief regulatory officer
2023-01-19	Duncan Jason	sold	-41,182.3	43.9044	-938	chief legal officer and gc
2023-01-19	STRECK PAUL	acquired	-	-	55,000	chief medical officer

About Albireo Pharma

Ronald H. W. Cooper

www.albireopharma.com

130

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

ALBO Income Statement

2022-09-30

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Revenue	$ 9,832	$ 3,664	$ 24,870	$ 8,058
Cost and operating expenses:
Cost of product revenue	612	431	1,622	431
Research and development	23,312	21,083	68,103	61,920
Selling, general and administrative	20,564	17,612	59,019	49,825
Other operating expense, net	1	3,719	7,544	7,873
Total cost and operating expenses	44,489	42,845	136,288	120,049
Operating loss	(34,657)	(39,181)	(111,418)	(111,991)
Other (loss) income:
Gain from sale of priority review voucher, net of transaction costs		103,387		103,387
Loss on extinguishment of debt	(613)		(613)
Interest expense, net	(2,530)	(3,331)	(8,152)	(10,675)
Net (loss) income before income taxes	(37,800)	60,875	(120,183)	(19,279)
Provision for income taxes	0	3,789	0	3,789
Net (loss) income	$ (37,800)	$ 57,086	$ (120,183)	$ (23,068)
Net (loss) income per share attributable to holders of common stock:
Basic (in dollars per share)	$ (1.92)	$ 2.96	$ (6.15)	$ (1.20)
Diluted (in dollars per share)	$ (1.92)	$ 2.90	$ (6.15)	$ (1.20)
Weighted-average common shares outstanding:
Basic (in shares)	19,655,350	19,258,905	19,541,044	19,197,536
Diluted (in shares)	19,655,350	19,651,243	19,541,044	19,197,536
Product
Revenue:
Revenue	$ 7,543	$ 1,060	$ 18,090	$ 1,060
Royalty
Revenue:
Revenue	$ 2,289	$ 2,604	$ 6,780	$ 6,998

ALBO Balance Sheet

2022-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 222,476	$ 248,107
Accounts receivable, net	2,029	3,272
Inventory	3,149	194
Prepaid expenses	8,516	5,261
Other current assets	2,666	12,096
Total current assets	238,836	268,930
Restricted cash	50,000
Property and equipment, net	1,303	668
Goodwill	17,260	17,260
Other assets	13,823	15,193
Total assets	321,222	302,051
Current liabilities:
Accounts payable	6,950	6,516
Accrued expenses	25,365	35,951
Other current liabilities	5,504	2,880
Total current liabilities	37,819	45,347
Liability related to sale of future royalties	62,053	60,132
Revenue interest liability, net	111,644
Note payable, net of discount		10,004
Other long-term liabilities	9,635	10,960
Total liabilities	221,151	126,443
Stockholders' Equity:
Preferred stock, $0.01 par value per share - 50,000,000 shares authorized at September 30, 2022 and December 31, 2021; 0 and 0 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
Common stock, $0.01 par value per share - 60,000,000 shares authorized at September 30, 2022 and December 31, 2021; 20,700,458 and 20,692,698 shares issued and outstanding at September 30, 2022, respectively, and 19,304,312 and 19,296,552 shares issued and outstanding at December 31, 2021, respectively	207	193
Additional paid-in capital	512,915	475,390
Accumulated other comprehensive income	8,212	1,105
Accumulated deficit	(421,033)	(300,850)
Treasury stock at cost, 7,760 shares at September 30, 2022 and December 31 2021, respectively	(230)	(230)
Total stockholders' equity	100,071	175,608
Total liabilities and stockholders' equity	$ 321,222	$ 302,051